UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
Filed
by the Registrant ☒
Filed
by a party other than the Registrant ☐
Check
the appropriate box:
| ☒ |
Preliminary
Proxy Statement |
| ☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2t2)) |
| ☐ |
Definitive
Proxy Statement |
| ☐ |
Definitive
Additional Materials |
| ☐ |
Soliciting
Material under §240.14a-12 |
Protagenic
Therapeutics, Inc.
(Name
of Registrant as Specified In Its Charter)
(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment
of Filing Fee (Check all boxes that apply):
| ☐ |
Fee
paid previously with preliminary materials. |
| ☐ |
Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
Protagenic
Therapeutics, Inc.
149
Fifth Avenue, Suite 500
New
York, NY 10010
PRELIMINARY
PROXY STATEMENT – SUBJECT TO COMPLETION, DATED FEBRUARY 26, 2025
NOTICE
OF SPECIAL MEETING OF STOCKHOLDERS
To
be held on April 18, 2025
Dear
Stockholders of Protagenic Therapeutics, Inc.:
Protagenic
Therapeutics, Inc., a Delaware corporation (“we,” “us,” “our,” or the “Company”), cordially
invites you to attend a special meeting of the Company’s stockholders, which will be held on April 18, 2025, at 10 a.m.,
Eastern time (the “Special Meeting”). will be conducted as a virtual meeting of stockholders via live webcast. We
believe that hosting a virtual meeting will enable greater stockholder participation from any location. Our board of directors has fixed
the close of business on February 27, 2025, as the record date for determining the stockholders entitled to notice of and to vote at
the Special Meeting and at any adjournment of the Special Meeting (the “Record Date”). Only stockholders of record
at the close of business on the record date may vote at the meeting or at any adjournment thereof. For ten days prior to the meeting,
a complete list of stockholders entitled to vote at the meeting will be available for examination by any stockholder, for any purpose
relating to the meeting, during ordinary business hours at our principal executive office principal offices at 149 Fifth Avenue, Suite
500, New York, NY 10010.
At
the Special Meeting, our stockholders will be asked to consider the following proposals which are more fully described in the
accompanying proxy statement:
| 1. |
To
grant the Board of Directors of the Company the discretionary authority to approve (in the event it is deemed necessary and advisable
by the Board) an amendment, at any time prior to January 31, 2026, to the Company’s Third Amended and Restated Certificate
of Incorporation to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per
share (the “Common Stock”) at a reverse split ratio ranging from any whole number between and including 1-for-10 and
1-for-20, with the exact ratio within such range and at such time to be chosen at the discretion of the Board of Directors, subject
to the Board of Directors’ authority to abandon the amendment (the “Reverse Stock Split Proposal”). |
| |
|
| 2. |
To
approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Reverse
Stock Split Proposal if there are not sufficient votes at the Special Meeting to approve and adopt the Reverse Stock Split Proposal (the
“Adjournment Proposal”). |
We
will also consider and take action upon such other matters as may properly come before the Special Meeting or any adjournment
or postponement thereof.
To
participate in the Special Meeting via the Internet, vote your shares electronically and submit your questions during the Special Meeting,
please visit www.virtualshareholdermeeting.com/PTIX2025SM. Registration to attend the Special Meeting virtually will open 15 minutes
prior to the start time, beginning at 9:45 a.m. Eastern Time. After you register, you will receive an email with instructions about attending
the Special Meeting, including a unique link to access the Special Meeting.
You
will not be able to attend the Special Meeting in person.
YOUR
VOTE IS IMPORTANT
Whether
or not you expect to attend via live webcast, your vote is important. The board of directors respectfully requests that you vote your
stock, regardless of the number of shares you own, in the manner described in the proxy statement. You may revoke your proxy in the
manner described in the proxy statement at any time before it has been voted at the Special Meeting.
Our
board of directors recommends a vote FOR Proposal One and Proposal Two.
| Sincerely, |
|
| |
|
| /s/
Garo H. Armen |
|
| Garo
H. Armen |
|
| Chairman |
|
TABLE
OF CONTENTS
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
The
statements in this Proxy Statement that are not historical statements, including statements regarding future capital-raising activities
and expected use of proceeds therefrom, our estimates regarding expenses, future revenues, capital requirements, needs for additional
financing, our ability to obtain additional financing, our success with regard to any clinical trials, our ability to recruit or retain
key personnel or to retain our executive officers, our stock price and ability to meet the continued listing requirements of The Nasdaq
Capital Market, and any other statements regarding our future expectations, beliefs, plans, objectives, financial conditions, assumptions
or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities
laws. These statements are subject to numerous risks and uncertainties, many of which are beyond our control, which could cause actual
results to differ materially from the results expressed or implied by the statements. We describe risks and uncertainties that could
cause actual results and events to differ materially in the “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the fiscal year ended December
31, 2023 (the “Annual Report”), which was filed on April 1, 2024, as amended on April 24, 2024, and as revised or supplemented
by our most recent Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, which was filed on November 14, 2024.
Any
forward-looking statements should be considered in light of such important factors. We undertake no obligation to revise or update publicly
any forward-looking statements for any reason. Readers are cautioned not to place undue reliance on any forward-looking statement, which
speaks only as of the date on which such statement is made.
All
subsequent written and oral forward-looking statements concerning the matters addressed in this Proxy Statement and attributable to us
or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in
this Proxy Statement.
PROTAGENIC
THERAPEUTICS, INC.
PROXY
STATEMENT
FOR
THE SPECIAL MEETING OF STOCKHOLDERS
TO
BE HELD ON APRIL 18, 2025
QUESTIONS
AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING
Why
am I receiving these materials?
The
board of directors (the “Board”) of Protagenic Therapeutics, Inc., a Delaware corporation (the “Company,” “we,”
“our,” or “us”), has delivered printed proxy materials to you by mail and is soliciting your proxy to vote at
the special meeting of stockholders (the “Special Meeting”) to be held on April 18, 2025 at 10:00 a.m. Eastern Time, or at
any adjournment or postponement of the meeting, for the purposes set forth in this proxy statement and in the accompanying notice of
special meeting of stockholders.
We
are holding the Special Meeting virtually by means of a live webcast. There will not be a physical meeting location and you will not
be able to attend in person. As a stockholder, you are invited to attend the Special Meeting online and are entitled and requested to
vote on the proposals described in this Proxy Statement. However, you do not need to attend the Special Meeting to vote your shares.
Instead, you may vote by the internet, by telephone or by mailing a proxy card or voting instruction form.
We
are making these proxy materials available to stockholders on or about March 7, 2025.
What
is included in these proxy materials?
These
proxy materials include the Notice of the Special Meeting, this proxy statement, and a proxy card.
What
am I voting on?
The
Board is soliciting your proxy in connection with the Special Meeting to be held on April 18, 2025 at 10:00 a.m. Eastern Time, and any
adjournment or postponement thereof. You are voting on the following proposals:
● Proposal
One: To grant the Board of Directors of the Company the discretionary authority to approve (in the event it is deemed necessary and advisable
by the Board) an amendment, at any time prior to January 31, 2026, to the Company’s Third Amended and Restated Certificate of Incorporation
to effect a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Common
Stock”) at a reverse split ratio ranging from any whole number between and including 1-for-10 and 1-for-20, with the exact ratio
within such range and at such time to be chosen at the discretion of the Board of Directors, subject to the Board of Directors’
authority to abandon the amendment (the “Reverse Stock Split Proposal”).; and
● Proposal
Two: To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor
of the Reverse Stock Split Proposal if there are not sufficient votes at the Special Meeting to approve and adopt the Reverse Stock Split
Proposal (the “Adjournment Proposal”).
How
does the Board recommend I vote?
Our
Board recommends that the stockholders vote their shares:
●
FOR the Reverse Stock Split Proposal; and
● FOR
the approval of the Adjournment Proposal.
Will
there be any other items of business addressed at the Special Meeting?
As
of the date of this proxy statement, we are not aware of any other matter to be presented at the Special Meeting. If any other matter
is properly brought before the Special Meeting, the proxy holders will vote on such matter in their discretion.
Who
can vote at the Special Meeting?
Only
stockholders at the close of business on February 27, 2025, the record date for the Special Meeting (the “Record Date”),
will be entitled to notice of and to vote at the Special Meeting or any adjournment or postponement thereof. As of the Record Date, there
were shares of our common stock outstanding and entitled to vote.
Stockholders
of Record: Shares Registered in Your Name. If on the Record Date, your shares of our common stock were registered directly in your
name with our transfer agent, Equiniti Trust Company, LLC, then you are a stockholder of record.
Beneficial
Owners: Shares Registered in the Name of a Broker or Bank. If on the Record Date, your shares of our common stock were held in an
account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in “street
name” and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered
the stockholder of record for purposes of voting at the Special Meeting. As a beneficial owner, you have the right to direct your broker
or other agent on how to vote the shares in your account or you may work with your broker to arrange to vote your shares directly at
the Special Meeting. You are also invited to participate in the Special Meeting. Your broker, bank or nominee (“broker”)
has enclosed or provided voting instructions for you to use to direct the broker on how to vote your shares.
How
do I vote?
Stockholders
of Record. If you are a stockholder of record, there are four ways to vote:
● By
internet at www.proxyvote.com. We encourage you to vote this way.
● By
touch tone telephone. Call toll-free at 1-800-690-6903.
● By
completing and mailing your proxy card.
● At
the Special Meeting: instructions on how to vote during the Special Meeting webcast are posted at www.virtualshareholdermeeting.com/PTIX2025SM.
Votes submitted during the Special Meeting must be received no later than the closing of the polls at the Special Meeting.
Whether
or not you plan to virtually attend the Special Meeting, we urge you to vote to ensure your vote is counted. You may still attend the
Special Meeting and vote your shares if you have already voted by proxy. Only the latest vote you submit will be counted. For instructions
on how to change your vote, see the “Can I change my vote or revoke my proxy?” section below.
Beneficial
Owners. If you hold your shares in “street name” as a beneficial owner of shares registered in the name of your broker,
you must vote your shares in the manner prescribed by your broker. Your broker has enclosed or otherwise provided a voting instruction
card for you to use in directing the broker how to vote your shares. Check the voting instruction card used by that organization to see
if it offers internet or telephone voting. We encourage you to vote by internet or telephone if offered by your broker.
Instead
of directing your broker how to vote your shares, you may elect to attend the Special Meeting and vote your shares during the meeting
if you obtain a legal proxy that gives you the right to vote the shares electronically via the internet at the Special Meeting. Instructions
on how to vote during the Special Meeting webcast are posted at www.virtualshareholdermeeting.com/PTIX2025SM. Votes submitted
during the Special Meeting must be received no later than the closing of the polls at the Special Meeting.
How
many votes do I have?
On
each matter to be voted upon at the Special Meeting, you have one vote for each share of common stock you owned as of the Record Date.
What
is the quorum requirement?
A
quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if at least one-third of the shares entitled to
vote at the Special Meeting are “present” at the Special Meeting. As of the Record Date, there were shares of our common
stock entitled to vote at the Special Meeting.
If
you are a stockholder of record, your shares will be counted as “present” at the Special Meeting if:
● You
attend and vote at the Special Meeting;
● You
have voted in advance by internet or telephone; or
● You
have properly submitted a proxy card.
If
your shares are held in street name, your shares will be counted as “present” at the Special Meeting if your broker has voted
on a discretionary item, or your broker has otherwise voted based on your instructions.
Abstentions
will be counted towards the quorum requirement. If there is no quorum, then the chair of the Special Meeting or a majority of the shares
present at the Special Meeting and entitled to vote may adjourn the meeting to another date until a quorum is present.
How
many votes are needed to approve each proposal?
The
table below shows the vote required to approve each of the proposals described in this proxy statement, assuming the presence of a quorum,
virtually or by proxy, at the Special Meeting.
| Proposal |
|
Voting
Options |
|
Vote
Required |
|
Effect
of Abstentions |
| Proposal
One: To approve the Reverse Split Proposal |
|
FOR,
AGAINST or ABSTAIN |
|
Affirmative
vote of the majority of votes cast on the proposal |
|
None |
| |
|
|
|
|
|
|
| Proposal
Two: To approve the Adjournment Proposal |
|
FOR,
AGAINST orABSTAIN |
|
Affirmative
vote of the majority of votes cast on the proposal |
|
None |
What
happens if I do not give specific voting instructions?
Stockholder
of Record. If you are a stockholder of record and you do not cast your vote, no votes will be cast on your behalf on any of the items
of business at the Special Meeting. However, if you submit a proxy but no instructions are given, the shares represented by the proxy
will be voted on your behalf in accordance with the recommendations of our Board as follows:
●
FOR the approval of the Reverse Stock Split Proposal; and
● FOR
the approval of the Adjournment Proposal.
In
the event other business properly comes before the Special Meeting or at any adjournment or postponement of the meeting, the individuals
named in the proxy will vote the shares represented by the proxy in their discretion.
Beneficial
Owner. For a beneficial owner of shares held in street name, if a proposal is deemed “routine” and you do not give instructions
to your broker or nominee, they may, but are not required to, vote your shares with respect to the proposal. If the proposal is deemed
“non-routine” and you do not give instructions to your broker or nominee, they may not vote your shares with respect to the
proposal and the shares will be treated as broker non-votes. The determination of whether a proposal is “routine” or “non-routine”
will be made by The Nasdaq Stock Market, LLC (“Nasdaq”) based on Nasdaq rules that regulate member brokerage firms. When
our inspector of election tabulates the votes for any particular matter, broker non-votes will be counted for purposes of determining
whether a quorum is present but may not otherwise be counted. We therefore encourage you to provide voting instructions on each proposal
to the organization that holds your shares. Because we anticipate Proposals One and Two are routine matters on which brokers may vote,
we do not anticipate any broker non-votes.
Can
I change my vote or revoke my proxy?
If
you are a stockholder of record, you may change your vote by revoking your proxy at any time before it is voted at the Special Meeting
in any one of the following ways:
● enter
a timely new vote by internet or telephone;
● submit
another properly completed, later-dated proxy card;
● send
a written notice that you are revoking your proxy to: Protagenic Therapeutics, Inc., 149 Fifth Avenue, Suite 500, New York, NY 10010,
Attention: Corporate Secretary, which must be received no later than April 17, 2025; or
● attend
the Special Meeting webcast and vote during the meeting. Attending the Special Meeting without voting during the meeting will not, by
itself, revoke a previously submitted proxy unless you specifically request your prior proxy be revoked.
If
you hold your shares in street name, contact your broker or other organization regarding how to revoke your instructions and change your
vote. Only your last-submitted, timely vote will count at the Special Meeting.
Who
counts the votes?
[ ] has been appointed inspector of election by the Company and will tabulate votes at the Special Meeting.
How
can I find out the voting results of the Special Meeting?
Preliminary
voting results will be announced at the Special Meeting. Final voting results will be published in a Current Report on Form 8-K to be
filed with the SEC within four business days after the Special Meeting.
How
can I attend the Special Meeting?
We
will be hosting the Special Meeting only by means of a live webcast. We believe that hosting a virtual meeting will enable greater stockholder
participation from any location. You will not be able to attend the Special Meeting in person. Registration will be open at 9:45 a.m.
Eastern Time on the day of the Special Meeting at www.virtualshareholdermeeting.com/ PTIX2025SM. Upon completing your registration,
you will receive further instructions that will allow you to access the Special Meeting.
How
can I submit a question at the Special Meeting?
You
may submit questions in advance of the Special Meeting at www.virtualshareholdermeeting.com/ PTIX2025SM after logging in with
your control number, but you will not be able to ask questions during the Special Meeting. We request that questions sent in advance
be submitted by April 17, 2025 at 5:00 p.m. Eastern Time. We expect to respond to questions during the Special Meeting that are pertinent
to the proposal at the Special Meeting. We may group together questions that are substantially similar to avoid repetition. Shortly after
the Special Meeting, we may post questions and answers under the Investors section of our website at https://protagenic.com/investor/corporate-governance/.
Information available on our website is not a part of, and is not incorporated into, this proxy statement.
What
if I experience technical difficulties when accessing the Special Meeting?
If
you have registered for the Special Meeting, you will receive a meeting access email on the day of the Special Meeting. Information regarding
technical support, including a technical support phone number will be provided in the meeting access email.
Can
I obtain a stockholder list?
A
stockholder list will be available for examination by our stockholders at our principal executive offices at 149 Fifth Avenue, Suite
500, New York, NY 10010 during ordinary business hours throughout the ten-day period prior to the Special Meeting for any purpose germane
to the Special Meeting.
What
does it mean if I receive more than one voting instruction card?
If
you receive more than one voting instruction card, your shares are registered in more than one name or are registered in different accounts.
Please vote using each voting instruction card to ensure that all of your shares are voted.
Where
can I view the proxy materials on the internet?
We
are making this proxy statement and voting instructions available to stockholders on or about March 7, 2025, at https://protagenic.com/investor/sec-filings/.
How
can I receive a printed copy of the proxy materials?
Stockholder
of Record. You may request a printed copy of the proxy materials by any of the following methods:
●
Internet download available at https://protagenic.com/investor/sec-filings/; or
●
E-mail at If requesting materials
by e-mail, please send a blank e-mail with your 12-digit control number in the subject line.
Beneficial
Owner. You may request a printed copy of the proxy materials by following the instructions provided to you by your broker.
In
addition, stockholders may request to receive proxy materials in printed form by mail or electronically by e-mail on an ongoing basis.
Choosing to receive your future proxy materials by e-mail will save us the cost of printing and mailing documents to you and will reduce
the environmental impact of printed materials.
Who
is paying for this proxy solicitation?
Our
Board is soliciting proxies for use at the Special Meeting, and we will bear the cost of the proxy solicitation. In addition to solicitation
by mail, our directors, officers and employees may solicit proxies personally, by telephone, email or other means of communication. We
will not compensate these persons for soliciting proxies on our behalf. We will reimburse brokerage firms and other persons representing
beneficial owners of shares for their expenses in forwarding solicitation material to such beneficial owners. We reserve the right to
use the services of a third-party solicitation firm to assist us in soliciting proxies.
PROPOSAL
1
THE
REVERSE STOCK SPLIT PROPOSAL
General
The
Board of Directors has approved a proposal to seek discretionary authority from the Company’s stockholders to approve an
amendment to our Third Amended and Restated Certificate of Incorporation (the “Amended and Restated Certificate of Incorporation”)
to combine the outstanding shares of our Common Stock into a lesser number of outstanding shares (a “Reverse Stock Split”).
If
approved by our stockholders, this proposal would permit (but not require) the Board of Directors to effect a Reverse Stock Split of
the outstanding shares of our Common Stock at any time prior to January 31, 2026, at a reverse split ratio ranging from any whole number
between and including 1-for-10 and 1-for-20, with the exact ratio within such range and at such time to be chosen at the discretion of
the Board of Directors, subject to the Board of Directors’ authority to abandon the amendment (the “Reverse Stock Split Proposal”).
In
fixing the ratio, the Board of Directors may consider, among other things, factors such as: the continued listing requirements of the
Nasdaq Capital Market; the number of shares of our Common Stock outstanding; potential financing opportunities; and prevailing general
market and economic conditions.
The
Reverse Stock Split Proposal, if approved by our stockholders, would grant the Company’s Board of Directors the
discretion to authorize a filing of the amendment to our Amended and Restated Certificate of Incorporation with the Secretary of
State of Delaware. The timing of the amendment will be determined by the Board of Directors based on its evaluation as to when such
action will be the most advantageous to our Company and our stockholders. In addition, the Board of Directors will be granted the
discretion, without further action by the stockholders, to abandon the amendment and the Reverse Stock Split if, at any time
prior to the effectiveness of the filing of the amendment with the Secretary of State of Delaware, the Board of Directors determines
that it is no longer in our best interest and the best interests of our stockholders to proceed.
The
proposed form of amendment to our Amended and Restated Certificate of Incorporation to affect the Reverse Stock Split is attached as
Appendix A to this Proxy Statement. Any amendment to our Amended and Restated Certificate of Incorporation to affect the Reverse Stock
Split will include the Reverse Stock Split ratio fixed by the Board, within the range approved by our stockholders.
Purpose
and Background of the Reverse Stock Split
On
February 26, 2025, the Board of Directors approved the proposal to seek discretionary authority from the Company’s stockholders
to approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split for the following
reasons:
| |
● |
The
Board of Directors believes that the reverse stock split is our best means of ensuring compliance with the $1.00 per share of Common
Stock minimum bid price requirement for continued listing on The Nasdaq Capital Market and avoid delisting; and |
| |
● |
The
Board of Directors believes that a higher stock price, which may be achieved through a reverse stock split, could help generate investor
interest in the Company and help attract, retain, and motivate employees. |
Nasdaq
Requirements for Continued Listing
Our
Common Stock is publicly traded and listed on The Nasdaq Capital Market under the symbol “PTIX.” One of the requirements
for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) is maintenance of a minimum closing bid
price of $1.00.
As
previously disclosed, on July 24, 2024, the Company received written notice from The Nasdaq Listing Qualifications department (“Nasdaq”)
notifying the Company that it was not in compliance with the requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on the
Nasdaq Capital Market as a result of the closing bid price of our Common Stock being below $1.00 per share for 30 consecutive business
days (the “Bid Price Rule”). Pursuant to an additional non-compliance letter from Nasdaq dated May 22, 2024, the Company
received a letter from Nasdaq indicating that, it did not meet the minimum $2,500,000 stockholders’ equity requirement for continued
listing as set forth in Nasdaq Listing Rule 5550(b)(1).
In
accordance with the terms of the previously imposed “Mandatory Panel Monitor” as that term is defined in Nasdaq Listing Rule
5815(d)(4)(B), the Nasdaq Listing Qualifications Staff (the “Staff”) did not grant the Company a grace period but rather
issued a delist determination, which has been stayed as a result of the Company requesting a hearing with the Nasdaq Hearings Panel (the
“Panel”). Further action by Nasdaq was stayed pending the issuance of the Panel’s decision and the expiration of any
extension that may be granted by the Panel to the Company as a result of the hearing, which was held on January 30, 2025.
On
February 19, 2025, the Company received written notice from Nasdaq notifying the Company that the Panel has determined to grant the request
of the Company to continue its listing on The Nasdaq Stock Market, subject to certain conditions, including regaining compliance with
Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1) on or before April 28, 2025. In the meantime, the Company’s common stock will remain
listed and eligible to trade on Nasdaq. There can be no assurance, however, that the Company will evidence compliance with all applicable
listing criteria prior to the expiration of any extension that was granted by the Panel to do so.
The
Board of Directors believes that effecting a reverse stock split may be the best means of increasing and maintaining the price of our
Common Stock to above $1.00 per share in compliance with the Bid Price Rule for continued listing on The Nasdaq Capital Market. The Board
of Directors believes that continued listing on The Nasdaq Capital Market provides overall credibility to an investment in our stock,
given the stringent listing and disclosure requirements of The Nasdaq Capital Market. Notably, some trading firms discourage investors
from investing in lower priced stocks that are traded in the over-the-counter market because they are not held to the same stringent
standards. Increasing visibility of our stock among a larger pool of potential investors could result in higher trading volumes. Such
increases in visibility and liquidity could also help facilitate future financings.
In
light of the factors mentioned above, our Board of Directors unanimously approved the proposed amendment to our Amended and Restated
Certificate of Incorporation to effect the reverse stock split as a potential means of increasing and maintaining the price of our Common
Stock to above $1.00 per share in order to maintain compliance with the Nasdaq listing requirements.
Potential
Increased Investor Interest
In
approving the proposed amendment to our Amended and Restated Certificate of Incorporation, the Board of Directors considered that our
Common Stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may
also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend
to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide
coverage of lower priced stocks.
Risks
Associated with the Reverse Stock Split
There
are risks associated with the reverse stock split, including that the reverse stock split may not result in a sustained increase in the
per share price of our Common Stock. There is no assurance that:
| |
● |
The
market price per share of our Common Stock after the reverse stock split will rise in proportion to the reduction in the number of
shares of our Common Stock issued immediately before the reverse stock split; |
| |
● |
The
reverse stock split will result in a per share price that will increase the level of investment in our Common Stock by institutional
investors or increase analyst and broker interest in our Company; |
| |
● |
The
reverse stock split will result in a per share price that will increase our ability to attract and retain employees and other service
providers; |
| |
● |
The
market price per share of our Common Stock will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq,
or that we will otherwise meet the requirements of Nasdaq for continued inclusion for trading on The Nasdaq Capital Market; and |
| |
● |
Nasdaq
may delist our Common Stock prior to the vote at the Special Meeting as the Nasdaq Hearings Panel’s final decision may arrive
before the Special Meeting date. |
Stockholders
should note that the effect of the reverse stock split, if any, upon the market price of our Common Stock cannot be accurately predicted.
In particular, we cannot assure you that the price of a share of our Common Stock after the reverse stock split will be ten (10) to twenty
(20) times, as applicable, the price for a share of our Common Stock immediately prior to the reverse stock split. Furthermore, even
if the market price of our Common Stock does rise following the reverse stock split, we cannot assure you that the market price of our
Common Stock immediately after the proposed reverse stock split will be maintained for any period of time. Even if an increased per-share
price can be maintained, the reverse stock split may not achieve the desired results that have been outlined above. Moreover, because
some investors may view the reverse stock split negatively, we cannot assure you that the reverse stock split will not adversely impact
the market price of our Common Stock.
The
market price of our Common Stock will also be based on our performance and other factors, some of which are unrelated to the reverse
stock split or the number of shares outstanding. If the reverse stock split is effected and the market price of our Common Stock declines,
the percentage decline as an absolute number and as a percentage of our overall market capitalization may be greater than would occur
in the absence of a reverse stock split. The total market capitalization of our Common Stock after implementation of the reverse stock
split when and if implemented may also be lower than the total market capitalization before the reverse stock split. Furthermore, the
liquidity of our Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse
stock split.
We
believe that the reverse stock split may result in greater liquidity for our stockholders. However, it is also possible that such liquidity
could be adversely affected by the reduced number of shares outstanding after the reverse stock split, particularly if the price of our
Common Stock does not increase as a result of the reverse stock split.
Even
if the reverse stock split is effected, we may not be able to satisfy all of the other requirements for continued listing of our Common
Stock on The Nasdaq Capital Market or other stock exchange. As discussed above, the Board approved the reverse stock split proposal and
is submitting it for approval by the stockholders with the primary intent of increasing the market price and minimum bid prices of our
Common Stock to regain and maintain compliance with the listing requirements of The Nasdaq Capital Market and to make our Common Stock
more attractive to a broader range of institutional and other investors. However, continued listing on such exchange requires compliance
with a variety of other qualitative and quantitative listing standards. Even if we effect the reverse stock split, we may not be able
to satisfy or maintain listing requirements on The Nasdaq Capital Market or any other stock exchange. We cannot provide any assurances
that we will be able to maintain a listing of the Common Stock on The Nasdaq Capital Market or any other stock exchange.
Mechanics
of the Reverse Stock Split
Effect
on Registered “Book-Entry” Holders of our Common Stock
Holders
of Common Stock hold some or all of their Common Stock electronically in book-entry or “street name” form under the direct
registration system for securities. These stockholders will not have stock certificates evidencing their ownership. They are, however,
provided with a statement reflecting the number of shares of Common Stock registered in their accounts. If you hold registered Common
Stock in book-entry form, you do not need to take any action to receive your post-split shares, if applicable.
Fractional
Shares
No
fractional shares will be issued in connection with the Reverse Stock Split. Shareholders of record who otherwise would be entitled to
receive fractional shares will be entitled to rounding up of their fractional share to the nearest whole share.
Potential
Effects of the Proposed Amendment
If
our stockholders approve the Reverse Stock Split Proposal and the Board implements it, the number of shares of Common Stock
issued and outstanding will be reduced, depending upon the ratio determined by the Board. The Reverse Stock Split will affect all holders
of our Common Stock uniformly and will not affect any stockholder’s percentage ownership interest in the Company, except that as
described below in “Fractional Shares,” record holders of Common Stock otherwise entitled to a fractional share as a result
of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split ratio will be entitled
to rounding up of their fractional share to the nearest whole share. For those stockholders who hold shares with a brokerage firm, the
Company intends to round up fractional shares at the participant level. The Reverse Stock Split will not affect any stockholder’s
proportionate voting power (subject to the treatment of fractional shares).
The
Reverse Stock Split will not change the terms of the Common Stock. Additionally, the Reverse Stock Split will have no effect on the number
of shares of Common Stock that we are authorized to issue. After the Reverse Stock Split, the shares of Common Stock will have the same
voting rights and rights to dividends and distributions and will be identical in all other respects to the Common Stock now authorized.
Our outstanding shares of Common Stock will remain fully paid and non-assessable.
After
the effective time of the Reverse Stock Split, we will continue to be subject to the periodic reporting and other requirements of the
Exchange Act.
Registered
“Book-Entry” Holders of Common Stock
Our
registered holders of Common Stock hold some or all of their shares electronically in book-entry form with the transfer agent. These
stockholders do not have stock certificates evidencing their ownership of the Common Stock. They are, however, provided with statements
reflecting the number of shares registered in their accounts.
Stockholders
who hold shares electronically in book-entry form with the transfer agent will not need to take action to receive evidence of their shares
of post-Reverse Stock Split Common Stock.
Holders
of Certificated Shares of Common Stock
Stockholders
holding shares of our Common Stock in certificated form will be sent a transmittal letter by the transfer agent after the effective time
of the Reverse Stock Split. The letter of transmittal will contain instructions on how a stockholder should surrender his, her or its
certificate(s) representing shares of our Common Stock (the “Old Certificates”) to the transfer agent. Unless a stockholder
specifically requests a new paper certificate or holds restricted shares, upon the stockholder’s surrender of all of the stockholder’s
Old Certificates to the transfer agent, together with a properly completed and executed letter of transmittal, the transfer agent will
register the appropriate number of shares of post-Reverse Stock Split Common Stock electronically in book-entry form and provide the
stockholder with a statement reflecting the number of shares registered in the stockholder’s account. No stockholder will be required
to pay a transfer or other fee to exchange his, her or its Old Certificates. Until surrendered, we will deem outstanding Old Certificates
held by stockholders to be cancelled and only to represent the number of shares of post-Reverse Stock Split common stock to which these
stockholders are entitled. Any Old Certificates submitted for exchange, whether because of a sale, transfer or other disposition of stock,
will automatically be exchanged for appropriate number of shares of post-Reverse Stock Split Common Stock. If an Old Certificate has
a restrictive legend on its reverse side, a new certificate will be issued with the same restrictive legend on its reverse side.
STOCKHOLDERS
SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY STOCK CERTIFICATE(S)
UNTIL REQUESTED TO DO SO.
Fractional
Shares
No
fractional shares will be issued in connection with the Reverse Stock Split. Shareholders of record who otherwise would be entitled to
receive fractional shares will be entitled to rounding up of their fractional share to the nearest whole share.
Effect
of the Reverse Stock Split on Outstanding Stock Options and Warrants
Based
upon the Reverse Stock Split ratio, proportionate adjustments are generally required to be made to the per share exercise price and the
number of shares issuable upon the exercise of all outstanding options and warrants. This would result in approximately the same aggregate
price being required to be paid under such options or warrants upon exercise, and approximately the same value of shares of Common Stock
being delivered upon such exercise immediately following the Reverse Stock Split as was the case immediately preceding the Reverse Stock
Split. The number of shares reserved for issuance pursuant to these securities will be reduced proportionately based upon the Reverse
Stock Split ratio.
Accounting
Matters
The
proposed amendment to our certificate of incorporation will not affect the par value of our Common Stock. As a result, at the effective
time of the Reverse Stock Split, the stated capital on our balance sheet attributable to the Common Stock will be reduced in the same
proportion as the Reverse Stock Split ratio, and the additional paid-in capital account will be credited with the amount by which the
stated capital is reduced. The per share net income or loss will be restated for prior periods to conform to the post-Reverse Stock Split
presentation.
No
Dissenters’ or Appraisal Rights
Under
the Delaware General Corporation Law, our stockholders are not entitled to any dissenters’ or appraisal rights with respect to
the Reverse Stock Split, and we will not independently provide stockholders with any such right.
Certain
Federal Income Tax Consequences of the Reverse Stock Split
The
following summary describes, as of the date of this proxy statement, certain U.S. federal income tax consequences of the Reverse Stock
Split to holders of our Common Stock. This summary addresses the tax consequences only to a U.S. holder, which is a beneficial owner
of our Common Stock that is either:
|
● |
an
individual citizen or resident of the United States; |
|
|
|
|
● |
a
corporation, or other entity taxable as a corporation for U.S. federal income tax purposes,
created or organized in or under the laws of the United States or any state thereof or the
District of Columbia; |
|
|
|
|
● |
an
estate, the income of which is subject to U.S. federal income taxation regardless of its
source; or |
|
|
|
|
● |
a
trust, if: (i) a court within the United States is able to exercise primary jurisdiction
over its administration and one or more U.S. persons has the authority to control all of
its substantial decisions or (ii) it was in existence before August 20, 1996 and a valid
election is in place under applicable Treasury regulations to treat such trust as a U.S.
person for U.S. federal income tax purposes. |
This
summary is based on the provisions of the Internal Revenue Code of 1986, as amended (the “Code”), U.S. Treasury regulations,
administrative rulings and judicial authority, all as in effect as of the date of this proxy statement. Subsequent developments in U.S.
federal income tax law, including changes in law or differing interpretations, which may be applied retroactively, could have a material
effect on the U.S. federal income tax consequences of the Reverse Stock Split.
This
summary does not address all of the tax consequences that may be relevant to any particular
investor, including tax considerations that arise from rules of general application to all
taxpayers or to certain classes of taxpayers or that are generally assumed to be known by
investors. This summary also does not address the tax consequences to (i) persons that may
be subject to special treatment under U.S. federal income tax law, such as banks, insurance
companies, thrift institutions, regulated investment companies, real estate investment trusts,
tax-exempt organizations, U.S. expatriates, persons subject to the alternative minimum tax,
persons whose functional currency is not the U.S. dollar, partnerships or other pass-through
entities, traders in securities that elect to mark to market and dealers in securities or
currencies, (ii) persons that hold our Common Stock as part of a position in a “straddle”
or as part of a “hedging transaction,” “conversion transaction” or
other integrated investment transaction for federal income tax purposes or (iii) persons
that do not hold our Common Stock as “capital assets” (generally, property held
for investment). This summary does not address backup withholding and information reporting.
This summary does not address U.S. holders who beneficially own Common Stock through a “foreign
financial institution” (as defined in Code Section 1471(d)(4)) or certain other non-U.S.
entities specified in Code Section 1472. This summary does not address tax considerations
arising under any state, local or foreign laws, or under federal estate or gift tax laws.
If
a partnership (or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our Common
Stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the
activities of the partnership. Partnerships that hold our Common Stock, and partners in such partnerships, should consult their own tax
advisors regarding the U.S. federal income tax consequences of the Reverse Stock Split.
Each
holder should consult his, her or its own tax advisors concerning the particular U.S. federal tax consequences of the Reverse Stock Split,
as well as the consequences arising under the laws of any other taxing jurisdiction, including any foreign, state, or local income tax
consequences.
General
Tax Treatment of the Reverse Stock Split
The
Reverse Stock Split is intended to qualify as a “reorganization” under Section 368 of the Code that should constitute a “recapitalization”
for U.S. federal income tax purposes. Assuming the Reverse Stock Split qualifies as a reorganization, a U.S. holder generally will not
recognize gain or loss upon the exchange of our shares for a lesser number of shares, based upon the Reverse Stock Split ratio. A U.S.
holder’s aggregate tax basis in the lesser number of shares received in the Reverse Stock Split will be the same such U.S. holder’s
aggregate tax basis in the shares of our Common Stock that such U.S. holder owned immediately prior to the Reverse Stock Split. The holding
period for the shares received in the Reverse Stock Split will include the period during which a U.S. holder held the shares of our Common
Stock that were surrendered in the Reverse Stock Split. The United States Treasury regulations provide detailed rules for allocating
the tax basis and holding period of the shares of our Common Stock surrendered to the shares of our Common Stock received pursuant to
the Reverse Stock Split. U.S. holders of shares of our Common Stock acquired on different dates and at different prices should consult
their tax advisors regarding the allocation of the tax basis and holding period of such shares.
THE
FOREGOING IS INTENDED ONLY AS A SUMMARY OF CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT, AND DOES NOT CONSTITUTE
A TAX OPINION. EACH HOLDER OF OUR COMMON STOCK SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF THE REVERSE STOCK
SPLIT TO THEM AND FOR REFERENCE TO APPLICABLE PROVISIONS OF THE CODE.
Interests
of Officers and Directors in this Proposal
Our
officers and directors do not have any substantial interest, direct or indirect, in this proposal.
Vote
Required
The
affirmative vote of the majority of votes cast on this proposal is required to approve the Reverse Stock Split Proposal. Proxies
solicited by the Board will be voted for approval of this proposal, unless otherwise specified. If stockholder approval for this proposal
is not obtained, then the Reverse Stock Split will not be affected.
Board
Recommendation
The
Board of Directors recommends a vote “FOR” the Reverse Stock Split Proposal.
PROPOSAL
2
THE
ADJOURNMENT PROPOSAL
General
In
addition to the Reverse Stock Split Proposal, our stockholders are also being asked to approve one or more adjournments of the Special
Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Reverse Stock Split Proposal, if there are insufficient
votes at the time of such adjournment to approve and adopt the Reverse Stock Split Proposal (the “Adjournment Proposal”).
If the Adjournment Proposal is approved, the Special Meeting could be successively adjourned to another date. In addition, the Board
could postpone the Special Meeting before it commences, whether for the purpose of soliciting additional proxies or for other reasons.
If the Special Meeting is adjourned for the purpose of soliciting additional proxies, stockholders who have already submitted their proxies
will be able to revoke them at any time prior to their exercise at the adjourned meeting.
Interest
of Certain Persons in Matters to Be Acted Upon
No
director or executive officer has any substantial interest, direct or indirect, by security holdings or otherwise, in this Proposal that
is not shared by all of our other stockholders.
Vote
Required
If
a quorum is represented at the Special Meeting, this Proposal 2 will be approved if the number
of votes cast “FOR” this proposal exceeds the number of votes cast “AGAINST”
this proposal. Abstentions are not considered votes cast and will have no effect on the outcome
of Proposal 2.
If
a quorum is not represented at the Special Meeting, this Proposal 2 will be approved if a majority of the votes cast at the Special Meeting
approves the proposal. In this case, abstentions and broker non-votes will have the effect of a vote “AGAINST” Proposal 2.
Board
Recommendation
The
Board of Directors recommends a vote “FOR” the Adjournment Proposal.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The
following table sets forth information regarding the beneficial ownership of the Common Stock as of April 1, 2024, unless otherwise indicated,
by (1) each person known by the Company to be the beneficial owner of more than 5% of the outstanding shares of common stock, (2) each
director of the Company, (3) the Company’s current executive officers, and (4) all current directors and executive officers of
the Company as a group. The persons and entities named in the table have sole voting and investment power with respect to all such shares
owned by them, unless otherwise indicated.
| Name and address of Beneficial Owner* | |
Amount and Nature of Beneficial Ownership | | |
Percent of Class | |
| | |
| | |
| |
| Garo H. Armen(1) | |
| 1,000,989 | (2) | |
| 21 | % |
| | |
| | | |
| | |
| Robert B. Stein(1) | |
| 158,906 | (3) | |
| 3 | % |
| | |
| | | |
| | |
| Khalil Barrage(1) | |
| 196,255 | (4) | |
| 4 | % |
| | |
| | | |
| | |
| Alexander K. Arrow(1) | |
| 244,773 | (5) | |
| 5 | % |
| | |
| | | |
| | |
| Brian J. Corvese(1) | |
| 54,479 | (6) | |
| 1 | % |
| | |
| | | |
| | |
| David A. Lovejoy | |
| 144,275 | (7) | |
| 3 | % |
| | |
| | | |
| | |
| Jennifer S. Buell(1) | |
| 76,563 | (8) | |
| 2 | % |
| | |
| | | |
| | |
| Andrew Slee(1) | |
| 110,859 | (9) | |
| 2 | % |
| | |
| | | |
| | |
| All directors and executive officers as a group (8 persons) | |
| 1,846,991 | (10) | |
| 35 | % |
*
Address for each party listed in the above table is c/o Protagenic Therapeutics, Inc., 149 Fifth Avenue, Suite 500, New York, NY 10010.
(1)
Executive officer and/or director.
(2)
Includes 738,489 shares of common stock. Also includes options to purchase 266,667 shares of common stock at an exercise price of $1.74,
$5.00 or $7.00 per share. Does not include options to purchase 245,833 shares that are not exercisable within 60 days of the date of
this report.
(3)
Represents options to purchase 158,906 shares of common stock at an exercise price of $1.74, $5.00, $7.00, or $22.40 per share. Does
not include options to purchase 76,094 shares that are not exercisable within 60 days of the date of this report.
(4)
Includes 150,880 shares of common stock and options to purchase 45,375 shares of common stock at an exercise price of $1.74, or $14.60
per share. Does not include options to purchase 22,125 shares that are not exercisable within 60 days of the date of this report.
(5)
Includes 45,815 shares of common stock and Includes options to purchase 198,958 shares of common stock at an exercise price of $1.74,
$4.00, $5.00 or $7.00 per share. Does not include options to purchase 98,333 shares that are not exercisable within 60 days of the date
of this report.
(6)
Includes options to purchase 54,479 shares of common stock at an exercise price of $7.00 per share. Does not include options to purchase
43,021 shares that are not exercisable within 60 days of the date of this report.
(7)
Includes 37,200 shares of common stock and options to purchase 107,075 shares of common stock in the aggregate with an exercise price
ranging from $4.00, $5.00, or $7.00 per share.
(8)
Includes options to purchase 76,568 shares of common stock at an exercise price of $1.74, $7.00 or $22.40 per share. Does not include
options to purchase 84,688 shares of common stock that are not exercisable within 60 days of the date of this report.
(9)
Includes options to purchase 110,859 shares of common stock at an exercise price of $1.74, $5.00, $7.00, or $22.40 per share. Does not
include options to purchase 106,641 shares of common stock that are not exercisable within 60 days of the date of this report.
(10)
Includes options to purchase 911,807 shares of common stock.
ADDITIONAL
INFORMATION
Procedure
for Submitting Stockholder Proposals
Stockholder
proposals intended for inclusion in our 2025 annual meeting proxy statement pursuant to Rule 14a-8 must be received by us no later than
September 8, 2025; provided that if the date of the 2025 annual meeting is moved more than 30 days before or after February 21, 2026
(which is the anniversary of this year’s annual meeting), we must receive notice of the stockholder proposal within a reasonable
time before we begin to print and mail our proxy materials. Any such proposal must comply with Rule 14a-8 of the Exchange Act.
In
addition to satisfying the foregoing requirements under our bylaws, to comply with the universal proxy rules, stockholders who intend
to solicit proxies in support of director nominees other than our nominees for the 2025 annual meeting of stockholders must provide notice
that sets forth the information required by Rule 14a-19 under the Exchange Act.
We
reserve the right to reject, rule out of order or take other appropriate action with respect to any proposal that does not comply with
these or other applicable requirements.
Householding
of Proxy Materials
Some
banks, brokers, and other nominee record holders may be participating in the practice of “householding” proxy statements
and annual reports. This means that only one copy of the Proxy Statement is being delivered to multiple stockholders sharing an address
unless we have received contrary instructions. We agree to deliver promptly, upon written or oral request, a separate copy of the proxy
materials, as requested, to any stockholder at the shared address to which a single copy of those documents was delivered. If you prefer
to receive separate copies of the proxy materials, contact Broadridge Financial Solutions, Inc. at 1-866-540-7095 or in writing at Broadridge,
Householding Department, 51 Mercedes Way, Edgewood, New York 11717. If you are currently a stockholder sharing an address with another
stockholder and wish to receive only one copy of future proxy materials for your household, please contact Broadridge at the above phone
number or address.
Transfer
Agent and Registrar
Equiniti
Trust Company, LLC is the transfer agent and registrar for our common stock.
OTHER
MATTERS
Our
Board is aware of no other matter that may be brought before the Special Meeting. Under Delaware law, only business that is specified
in the notice of Special Meeting to stockholders may be transacted at the Special Meeting.
WHERE
YOU CAN FIND MORE INFORMATION
We
file reports, proxy statements and other information with the SEC as required by the Exchange Act. The registration statement contains
exhibits and other information that are not contained in this proxy statement. The descriptions in this proxy statement of the provisions
of documents filed as exhibits to the registration statement are only summaries of those documents’ material terms. You can read
the Company’s SEC filings, including this proxy statement, over the Internet at the SEC’s website at http://www.sec.gov.
Appendix
A
Amendment
to Third Amended and Restated Certificate of Incorporation of the Company
CERTIFICATE
OF AMENDMENT
OF
THIRD
AMENDED AND RESTATED RESTATED CERTIFICATE OF INCORPORATION
OF
PROTAGENIC
THERAPEUTICS, INC.
Protagenic
Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware
(the “Company”), does hereby certify as follows:
| FIRST: |
|
That,
the Board of Directors of the Company duly adopted resolutions by unanimous written consent in accordance with Sections 141(f) and
242 of the General Corporation Law of the State of Delaware, recommending and declaring advisable that the Third Amended and Restated
Certificate of Incorporation of the Company be amended and that such amendment be submitted to the stockholders of the Corporation
for their consideration, as follows: |
| |
|
| |
|
RESOLVED,
that the first sentence of Article FOURTH of the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended
and/or restated to date, be amended and restated in its entirety to read as follows: |
| |
|
| |
|
“That,
effective on the filing of this Certificate of Amendment of Third Amended and Restated Certificate of Incorporation with the Office
of the Secretary of State of the State of Delaware (the “Effective Time”), a one-for-[*] reverse stock split of the Corporation’s
Common Stock shall become effective, pursuant to which each [*] shares of Common Stock outstanding and held of record by each stockholder
of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one
validly issued, fully-paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon
the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination
of shares, the “Reverse Stock Split”). The par value of the Common Stock following the Reverse Stock Split shall remain
at $0.0001 per share. No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split. In lieu thereof,
(i) with respect to holders of one or more certificates which formerly represented shares of Common Stock that were issued and outstanding
immediately prior to the Effective Time, upon surrender after the Effective Time of such certificate or certificates, any holder
who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective
Time, shall be entitled to receive a cash payment (the “Fractional Share Payment”) equal to the fraction of which such
holder would otherwise be entitled multiplied by the closing price per share on the trading day immediately preceding the Effective
Time as reported by The Nasdaq Capital Market (as adjusted to give effect to the Reverse Stock Split); provided that, whether or
not fractional shares would be issuable as a result of the Reverse Stock Split shall be determined on the basis of (a) the total
number of shares of Common Stock that were issued and outstanding immediately prior to the Effective Time formerly represented by
certificates that the holder is at the time surrendering and (b) the aggregate number of shares of Common Stock after the Effective
Time into which the shares of Common Stock formerly represented by such certificates shall have been reclassified; and (ii) with
respect to holders of shares of Common Stock in book-entry form in the records of the Company’s transfer agent that were issued
and outstanding immediately prior to the Effective Time, any holder who would otherwise be entitled to a fractional share of Common
Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive the Fractional Share Payment
automatically and without any action by the holder. |
| |
|
The
total number of shares of stock which the Corporation is authorized to issue is 120,000,000, consisting of 100,000,000 shares of
common stock, at a par value of $0.0001 per share (“Common Stock”), and 20,000,000 shares of preferred stock, at a par
value of $0.000001 per share (“Preferred Stock”).” |
| |
|
| SECOND: |
|
That,
at a special meeting of stockholders of the Corporation, the aforesaid amendment was duly adopted by the stockholders of the Corporation. |
| |
|
| THIRD: |
|
That,
the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the General Corporation Law
of the State of Delaware. |
IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer
on this day
of , 2025.
| PROTAGENIC
THERAPEUTICS, INC. |
|
| |
|
|
| By: |
|
|
Alexander K. Arrow
Chief
Financial Officer |
|
Protagenic Therapeutics (NASDAQ:PTIXW)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Protagenic Therapeutics (NASDAQ:PTIXW)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
